Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results by Güler, Serdar et al.
ORIGINAL ARTICLE
Improved Glycaemic Control with Biphasic Insulin Aspart 30
in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs:
PRESENT Study Resultsadi_015 23..33
Serdar Güler, MD,* Surendra Kumar Sharma, MD,
† Majeed Almustafa, MD, ChB, MRCP (UK),
FRCP (Ed.),
‡ Chong Hwa Kim, MD, PhD,
§ Sami Azar, MD, FACP,
¶ Rucsandra Danciulescu, MD, PhD,**
Marina Shestakova, MD, PhD,
†† Duma Khutsoane, MD, MMed Intern(ufs), FCP(SA),
‡‡ and
Ole Molskov Bech, MD, MBA
§§ for the PRESENT Study Group
*Ankara Numune Training and Research Hospital, Ankara, Turkey;
†M G Medical College, Jaipur, India;
‡Al Mstansiriya
University, Baghdad, Iraq;
§Sejong General Hospital, Bucheon City, South Korea;
¶American University of Beirut, Beirut,
Lebanon; **N. Paulescu Institute, Bucharest, Romania;
††Federal Scientiﬁc Centre of Endocrinology, Moscow, Russia;
‡‡Medi-Clinic, Bloemfontein, South Africa;
§§Novo Nordisk International Operations Clinical Development Centre, Beijing,
China
DOI: 10.1111/j.1753-5174.2008.00015.x
ABSTRACT
Aims. This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30)
treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp
30 + alpha-glucosidase inhibitors (GI), and BIAsp 30 + BI + thiazolidinediones (TZD) after failing oral antidiabetic
drugs (OADs) treatment.
Methods. This was a multi-national, multi-centre, six-month, prospective, open-labelled, uncontrolled, clinical
experience evaluation study, with the exception of a three-month study in one country (China) (“all exclude China”
and “China”). Initiation and discontinuation of BIAsp 30 treatment were entirely at the discretion of the attending
physicians.
Results. Mean HbA1c, FPG and PPPG were signiﬁcantly reduced from baseline at three and six months in all groups
(P < 0.001). In “all exclude China”, reductions in mean HbA1c, FPG and PPPG at six months were as follows: BIAsp
30-only group (-2.12  1.76% points; -4.82  3.86 mmol/L; -6.89  4.74 mmol/L), BIAsp 30 + BI group
(-2.24  1.77% points; -4.48  3.68 mmol/L; -6.66  4.55 mmol/L), BIAsp 30 + SU group (-1.95  1.59%
points; -3.98  3.19 mmol/L; -6.25  4.45 mmol/L) and BIAsp 30 + SU + BI group (-1.78  1.20% points;
-3.57  2.78 mmol/L; -5.89  3.98 mmol/L). The only serious adverse drug reaction was reported by the BIAsp
30-only group. In the “China” group, reductions in mean HbA1c, FPG and PPPG at three months were: BIAsp
30-only group (-2.16  1.52% points; -3.34  2.49 mmol/L; -6.29  3.92 mmol/L), BIAsp 30 + BI group
(-2.44  1.52% points; -4.01  2.50 mmol/L; -7.10  3.96 mmol/L), BIAsp 30 + GI group (-2.33  1.41%
points; -4.34  2.52 mmol/L; -7.97  3.99 mmol/L) and BIAsp 30 + BI + TZD group (-1.21  1.60% points;
-3.50  2.29 mmol/L; -5.97  3.39 mmol/L). No serious ADR were reported in China. The most frequent
hypoglycaemic episodes were diurnal and minor in nature.
Conclusions. BIAsp 30 treatment in a clinical setting improved glycaemic control in type 2 diabetes patients failing
OADs.
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A poster based on the preliminary results was presented at the American Diabetes Association conference in Chicago, USA,
from 22 to 26 June 2007 [1].
This study was sponsored by Novo Nordisk International Operations.
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T
he progressive nature of type 2 diabetes mel-
litus will require most patients to intensify
their therapies in order to maintain good glycae-
mic control in the longer term [2]. Intensiﬁcation
of therapy has been shown to reduce the risk of
many complications associated with type 2 diabe-
tes [3]. There are various options for initiating
insulin treatment in insulin-naïve patients.
According to the recent consensus statement from
the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes
(EASD), patients experiencing poor glycaemic
control with lifestyle interventions and oral
antidiabetic drugs (OADs) should intensify their
treatment with the addition of insulin [4]. For
newly diagnosed patients with severely uncon-
trolled diabetes with catabolism, fasting plasma
glucose (FPG) levels above 13.9 mmol/L, random
glucose levels consistently above 16.7 mmol/L or
HbA1c above 10%, insulin therapy in combination
with lifestyle change is the treatment of choice [4].
Insulin is effective in lowering hyperglycaemia,
with potential beneﬁcial effects on triglyceride and
HDL cholesterol levels [4,5]. Its disadvantage
remains its potential to induce weight gain and
cause hypoglycaemia. Patients treated with a com-
bination of insulin + OADs have beneﬁted from
the insulin-sparing effects of some OADs, which
allow a lower dose of insulin to be used, thereby
reducing the potential for hypoglycaemia [2,6]. A
Cochrane review of 20 randomised controlled
trials has shown that insulin + OAD combination
therapy was associated with a 43% relative reduc-
tion in total daily insulin requirement, compared
with insulin monotherapy [7]. The choice of gly-
caemic goals and the medications used to achieve
them must be individualised for each patient, bal-
ancing the potential for lowering HbA1c and
anticipated long-term beneﬁt with speciﬁc safety
issues and other characteristics of regimens,
including side effects, tolerability, patient burden,
long-term adherence, cost and the effects of the
medications on hypertension and dyslipidaemia
[4].
Biphasic insulin aspart 30 (BIAsp 30; NovoMix
®
30, Novo Nordisk, Bagsvaerd, Denmark) is a pre-
mixed insulin analogue that contains both rapid-
acting insulin aspart and long-acting protaminated
insulin aspart in the ratio 30:70 respectively. Its
safety and efﬁcacy have been demonstrated in
numerous randomised clinical trials [8–15]. It has
been used successfully alone or in combination
with the majority of marketed OADs, such as bigu-
anides (BI) [8,16] and thiazolidinediones (TZD)
[17].
While the efﬁcacy and safety of BIAsp 30 in
randomised controlled clinical trials have been
established in the literature, data on its use in
routine clinical practice situations remain limited.
The Physicians’ Routine Evaluation of Safety and
Efﬁcacy of NovoMix
® 30 Therapy (PRESENT)
Study is the largest, multi-national, observational
study on BIAsp 30 in real clinical settings com-
pleted to date. It aims to collect data complemen-
tary to the published clinical data on the safety and
efﬁcacy of BIAsp 30 use in type 2 diabetes. In this
article, we present results from a subgroup poorly
controlled (with HbA1c  7% at baseline) on
OADs and who either added BIAsp 30 treatment
to their existing OADs or transferred to BIAsp 30
monotherapy. The patient data were categorised
according to the type of therapy received through-
out the study, i.e., BIAsp 30 only or combination of
BIAsp 30 with OADs (sulphonylureas or bigu-
anides or sulphonylureas+biguanides).
Patients and Methods
Study Design andTreatment
This was a multi-national, multi-centre, six-
month, prospective, open-labelled, uncontrolled,
clinical experience evaluation study. The objective
of this observational study was to evaluate the efﬁ-
cacy and safety of using BIAsp 30, as a mono-
therapy or in combination with OADs, for type 2
diabetes management in routine clinical practice.
The requirement for ethics committee approval or
patient informed consent for this study was
according to local regulations. In two participating
countries, ethics committee approval was required
but patient informed consent was not required. In
another two participating countries, both ethics
committee approval and patient informed consent
were required. For the other countries, both ethics
committee and patient informed consent approv-
als were not obtained as these were not required.
As this was an observational study, the initiation
and discontinuation of BIAsp 30 treatment were
entirely at the discretion of the attending physi-
cians and no intervention was added to the physi-
cian’s routine practice. Except for patients in one
country, all patients purchased their own biphasic
insulin aspart 30 as in routine clinical practice. No
special investigational procedures outside clinical
practice were planned.
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As this was an observational study, the only criteria
were that patients had type 2 diabetes mellitus,
were inadequately controlled on their current
therapy and were prescribed BIAsp 30 as mono-
therapy or in combination with OADs in accor-
dance with the approved labelling. In this paper,
we present data from insulin-naïve patients with a
baseline HbA1c of 7% who were previously
treated only with OADs.
Participating Countries
Thisstudywasplannedfor15countries[18]:China
(N = 11,724), India (N = 3,560), Iraq (N = 2,031),
Jordan (N = 380), Lebanon (N = 685), Romania
(N = 1,227), Russia (N = 2,256), Saudi Arabia and
the Gulf countries (N = 2,228) which includes
Kuwait, Qatar and the United Arab Emirates,
South Africa (N = 1,510), South Korea (N = 831),
Sri Lanka (N = 81), and Turkey (N = 3,149).
However, data from Sri Lanka were excluded from
this paper because data were collected only at base-
line. The data presented here are from the remain-
ing 14 countries, with data from China presented
separately as data were collected for 3 months only.
Data Collection and Study Endpoints
The efﬁcacy endpoints were the changes in HbA1c,
FPG and postprandial plasma glucose (PPPG) at
the end of treatment from baseline. The safety
endpoints were the occurrence of hypoglycaemic
episodes and adverse drug reactions (ADRs).
Patient data were collected at baseline, three
months and six months using standardised forms.
These were patient demography (at baseline),
weight, duration of diabetes, current diabetes
therapy, HbA1c, FPG and PPPG measurements,
number of hypoglycaemic episodes and ADRs.
Hypoglycaemic episodes and ADRs were based on
patient recollection and clinical records from three
months prior to baseline visit and from the last
visit for three- and six-month datapoints. Major
episodes were deﬁned as those where the patient
was unable to perform self-treatment, i.e., glucose
had to be administered to the patient by another
person. Daytime (diurnal) episodes occurred
between 06:00 to 00:00.
Statistical Analyses
The patients were categorised into groups accord-
ing to the therapies received constantly during the
study: BIAsp 30-only, BIAsp 30 + sulphonylureas
(SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU
+ BI, BIAsp 30 + alpha glucosidase inhibitors (GI),
and BIAsp 30 + BI + thiazolidinediones (TZD).
These BIAsp 30 + OAD combinations had the
largest sample sizes in the study population.
Patients who had changes in therapy during the
study period were not included in this sub-
analysis. Other combinations were omitted
because their sample sizes were too small for
meaningful analysis. The safety analysis set con-
sisted of enrolled patients with baseline data.
Hence, patients who withdrew from the study but
who have baseline data are included in the analysis
and contribute with whatever data that is available.
Baseline demographic information, diabetes
therapy, and efﬁcacy and safety outcomes were
presented as descriptive statistics (%, mean  S.D.
and 95% conﬁdence interval). Changes in HbA1c,
FPG and PPPG from baseline were analysed using
the paired t-test. Baseline and demographic vari-
ables (patients’ country, gender, weight, body mass
index [BMI], ethnicity, age, duration of diabetes,
HbA1c at baseline, total daily dose of BIAsp 30 per
body weight [bw], previous OAD treatment) and
current treatment were ﬁtted into a generalised
linear model to determine the factors that affected
the change in HbA1c at six months from baseline.
Hypoglycaemic episodes and ADRs were pre-
sented according to category and severity using
summary statistics and event rates. All the statisti-
cal analyses were performed using SAS
® version
9.1.3 (SAS Institute, NC, USA).
Results
Subject Disposition, Baseline Demography and Prior
OAD Exposure
Table 1 shows the disposition of subjects by the
type of therapy during the study. The safety popu-
lation in the BIAsp 30-only group (N = 2,507 and
Table 1 Subject disposition
All exclude
China China
Enrolled 22,857 11,724
Safety population 21,977 11,662
OAD therapy only and HbA1c  7% 8,151 4,551
Therapy during study*
BIAsp 30 only 2,507 2,464
BIAsp 30 + BI 1,062 541
BIAsp 30 + SU 269 NA
BIAsp 30 + SU + BI 489 NA
BIAsp 30 + GI NA 165
BIAsp 30 + BI + TZD NA 156
*Only presented for the four most common type of therapy.
BI = biguanides; GI = glucosidase inhibitors; MEG = meglitinides; NA = not
applicable; SU = sulphonylureas; TZD = thiazolidinediones.
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BIAsp 30 + OAD combination in both the “all
exclude China” and “China” groups (Table 1). In
“all exclude China”, the majority of patients com-
pleted the six-month study (88% to 91% across
the groups), while a small proportion continued
the study until three months (9% to 13% across
the groups). Baseline BMI, HbA1c, FPG and
PPPG were lowest in the BIAsp 30 + SU + BI
group (Table 2a). The most common prior OAD
treatments among the groups were SU + BI and
SU-only (Table 3a). In the “China” group, base-
line BMI, HbA1c, and FPG were lowest in the
BIAsp 30-only group while PPPG was low in both
the BIAsp 30-only and BIAsp 30 + BI + TZD
groups (Table 2b). The most common prior OAD
treatments among the groups were SU + BI and
BI-only (Table 3b). Since the dosage of SU was not
analysed due to the many types available, the
dosage of OADs used during the study will not be
discussed.
BIAsp 30 Exposure During Study
BIAsp 30 dosage per body weight at three and six
months increased from baseline in all the groups
(Table 4a, b). At all visits in the “all exclude China”
group, the mean dosage was higher in the BIAsp
30-only and BIAsp 30 + BI groups and lower in the
BIAsp 30 + SU and BIAsp 30 + SU + BI groups. In
all the groups, the majority of patients followed
a twice-daily injection regimen of BIAsp 30.
However, a substantial proportion of patients in
the BIAsp 30 + SU and BIAsp 30 + SU + BI
groups injected only once daily. In the “China”
Table 2 (a) Baseline characteristics—all exclude China; (b) Baseline characteristics—China
Characteristics BIAsp 30 only BIAsp 30 + SU BIAsp 30 + BI BIAsp 30 + SU + BI
Safety population 2,507 269 1,062 489
Gender, N (% males) 2,492 (49.7) 267 (40.8) 1,057 (48.0) 487 (59.8)
Ethnicity, N 2,474 266 1,023 483
Asian,* % 38.4 54.1 31.4 84.9
White, % 36.0 34.2 32.6 5.0
Middle Eastern,
† % 21.0 10.5 25.8 8.7
Other, % 4.6 1.2 10.2 1.4
Mean age, N; years  SD 2,056;
55.8  11.6
224;
56.2  11.2
845;
53.8  11.3
410;
55.9  10.6
Mean diabetes duration, N; years  SD 2,373;
9.0  6.1
244;
8.7  6.6
989;
8.5  5.9
467;
9.2  5.7
Mean BMI,N; kg/m
2  SD 2,448;
26.6  4.7
266;
26.5  4.9
1,032;
29.1  5.2
485;
26.0  4.5
Mean HbA1c,N ;% SD 2,507;
9.8  1.8
269;
9.5  1.6
1,062;
9.9  1.8
489;
9.3  1.5
Mean FPG, N; Mmol/L  SD 2,428;
13.0  4.1
261;
11.8  3.4
1,018;
12.4  3.7
488;
10.7  3.0
Mean PPPG, N; mmol/L  SD 2,392;
17.6  4.8
255;
16.8  4.3
1,008;
16.9  4.5
483;
15.7  4.0
Characteristics BIAsp 30 only BIAsp 30 + BI BIAsp 30 + GI BIAsp 30 + BI + TZD
Safety population 2,464 541 165 156
Gender, N (% males) 1,396 (56.7) 301 (55.6) 78 (47.3) 81 (51.9)
Ethnicity, N 2,462 540 165 156
Asian,* % 100 99.8 100 100
White, % <0.1% 0.2 0 0
Mean age, N; years  SD 2,448;
54.1  10.9
533;
53.9  11.0
164;
57.6  10.6
154;
58.0  10.8
Mean diabetes duration, N; years  SD 2,424;
5.2  4.2
529;
5.6  3.8
162;
5.5  4.1
153;
5.6  3.4
Mean BMI,N; kg/m
2  SD 2,461;
23.9  2.7
537;
24.6  2.7
164;
24.2  2.7
156;
25.1  1.9
Mean HbA1c,N ;% SD 2,464;
9.1  1.6
541;
9.6  1.9
165;
9.2  1.6
156;
9.2  1.4
Mean FPG, N; mmol/L  SD 2,462;
10.5  2.6
541;
11.4  2.9
165;
11.5  2.6
145;
10.8  2.4
Mean PPPG, N; mmol/L  SD 2,463;
15.4  4.0
541;
16.6  4.2
165;
17.4  4.0
155;
15.3  3.8
*Asian includes Paciﬁc Islander.
†Middle Eastern includes Arab.
BI = biguanides; SU = sulphonylureas; FPG = fasting plasma glucose; PPPG = postprandial plasma glucose; GI = alpha-glucosidase inhibitors;
TZD = thiazolidinediones.
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the BIAsp 30 + BI + TZD group (Table 4b). In all
the groups, the majority of patients followed a
twice-daily injection regimen of BIAsp 30.
Efﬁcacy
In the “all exclude China” group, mean HbA1c,
FPG and PPPG were signiﬁcantly reduced from
baseline at three and six months in all groups
(P < 0.001) (Table 5a). Reductions in mean HbA1c,
FPG and PPPG after 6 months were as follows:
BIAsp 30-only (-2.12  1.76% points, -4.82 
3.86 mmol/L and -6.89  4.74 mmol/L), BIAsp
30 + BI group (-2.24  1.77% points, -4.48 
3.68 mmol/L and -6.66  4.55 mmol/L), BIAsp
30 + SU group (-1.95  1.59% points, -3.98 
3.19 mmol/L and -6.25  4.45 mmol/L) and
BIAsp 30 + SU + BI group (-1.78  1.20% points,
-3.57  2.78 mmol/L and -5.89  3.98 mmol/L).
The proportion of patients who achieved an HbA1c
of less than 7% at six months was as follows: BIAsp
30 + SU (29%), BIAsp 30 + BI (29%), BIAsp
30 + SU + BI groups (31%), and BIAsp 30-only
group (23%). Further, a small proportion of
patients achieved target HbA1c without reporting
hypoglyceamic episodes (ranging from 21% to
32% across the groups). Based on the generalised
linear model, patients’ country, ethnicity, age,
baseline HbA1c and total daily dose of BIAsp 30 per
bw were found to have signiﬁcant effects on the
change in HbA1c at six months from baseline
(P < 0.01).
In the “China” group, mean HbA1c, FPG and
PPPG were signiﬁcantly reduced from baseline at
three months in all groups (P < 0.001) (Table 5b).
Reductions in mean HbA1c, FPG and PPPG
after 3 months were as follows: BIAsp 30-only
(-2.16  1.52% points, -3.34  2.49 mmol/L and
-6.29  3.92 mmol/L), BIAsp 30 + BI group
(-2.44  1.52% points, -4.01  2.50 mmol/L and
-7.10  3.96 mmol/L), BIAsp 30 + GI group
(-2.33  1.41% points, -4.34  2.52 mmol/L
and -7.97  3.99 mmol/L) and BIAsp 30 + BI +
TZD group (-1.21  1.60% points, -3.50 
2.29 mmol/L and -5.97  3.39 mmol/L). The
proportion of patients who achieved an HbA1c of
less than 7% at three months was as follows: BIAsp
30-only (55%), BIAsp 30 + BI (49%), BIAsp
30 + GI (61%), and BIAsp 30 + BI + TZD (19%).
Further, a small proportion of patients achieved
target HbA1c without reporting hypoglyceamic
episodes (ranging from 47% to 64% across the
groups). Based on the generalised linear model,
duration of diabetes, baseline HbA1c, total daily
dose of BIAsp 30 per bw, previous OAD treatment,
and current treatment were found to have signiﬁ-
cant effects on the change in HbA1c at three
months from baseline (P < 0.01).
Table 3 (a) OAD therapy prior to the study—all exclude China; (b) OAD therapy prior to the study—China
BIAsp 30 only BIAsp 30 + SU BIAsp 30 + BI BIAsp 30 + SU + BI
N (% patients)
Safety population 2,507 269 1,062 489
SU 670 (26.7) 157 (58.4) 73 (6.9) 21 (4.3)
BI 100 (4.0) 1 (0.4) 126 (11.9) 4 (0.8)
GI 18 (0.7) 0 (0.0) 1 (0.1) 1 (0.2)
TZD 11 (0.4) 1 (0.4) 4 (0.4) 0 (0.0)
MEG 28 (1.1) 3 (1.1) 2 (0.2) 0 (0.0)
Combinations of OADs
SU + BI 959 (38.3) 73 (27.1) 566 (53.3) 400 (81.8)
SU + BI + TZD 123 (4.9) 6 (2.2) 82 (7.7) 28 (5.7)
Other combinations 598 (23.9) 28 (10.4) 208 (19.5) 35 (7.2)
BIAsp 30 only BIAsp 30 + BI BIAsp 30 + GI BIAsp 30 + BI + TZD
N (% patients)
Safety population 2,464 541 165 156
SU 464 (18.8) 47 (8.7) 16 (9.7) 4 (2.6)
BI 433 (17.6) 162 (29.9) 9 (5.5) 5 (3.2)
Alpha-GI 167 (6.8) 1 (0.2) 27 (16.4) 1 (0.6)
TZD 59 (2.4) 4 (0.7) 0 0
MEG 203 (8.2) 4 (0.7) 3 (1.8) 0
Combinations of OADs
SU + BI 524 (21.3) 217 (40.1) 33 (20.0) 14 (9.0)
SU + BI + TZD 14 (0.6) 4 (0.7) 2 (1.2) 101 (64.7)
Other combinations 600 (24.4) 102 (18.9) 75 (45.5) 31 (19.9)
BI = biguanides; GI = glucosidase inhibitors; MEG = meglitinides; SU = sulphonylureas; TZD = thiazolidinediones.
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The only serious ADR (classiﬁed under the cat-
egory of unspeciﬁed events) in the “all exclude
China” group was reported in the BIAsp 30-only
group. Non-serious ADRs were reported in the
BIAsp 30-only group (6 events), BIAsp + BI group
(53 events) and BIAsp 30 + SU + BI group (28
events). The ADRs were classiﬁed as symptoms of
hypersensitivity, acute painful neuropathy, refrac-
tion disorders, worsening of diabetic retinopathy,
lipodystrophy, oedema and other unspeciﬁed
events. In the “China” group, all ADR were non-
serious in nature and reported in the BIAsp
30-only group (11 events), BIAsp 30 + BI group (9
events), BIAsp 30 + GI group (2 events) and none
were reported in the BIAsp 30 + BI + TZD group.
The ADRs were classiﬁed as symptoms of hyper-
sensitivity, lipodystrophy or oedema.
In “all exclude China”, most of the hypogly-
caemic episodes were reported at three months
(1,303 episodes in the BIAsp-only group, 175
episodes in the BIAsp 30 + SU group, 880 epi-
sodes in the BIAsp 30 + BI group and 190 epi-
sodes in the BIAsp 30 + SU + BI group) and fewer
episodes were reported at six months (963, 46,
637 and 239 episodes, respectively). When
expressed as the number of episodes/patient year,
the number of hypoglycaemic episodes/patient
year at the end of study vs. baseline were as
follows: BIAsp 30-only group (1.91 vs. 2.08),
BIAsp 30 + BI group (3.00 vs. 1.86), and BIAsp
30 + SU group (1.73 vs. 2.75), BIAsp
30 + SU + BI group (1.87 vs. 2.29). Generally the
most frequent hypoglycaemic episodes were
diurnal and minor in nature (Figure 1). The rate
of diurnal episodes increased from baseline in the
BIAsp 30-only and BIAsp 30 + BI group. The rate
of major episodes in the BIAsp 30 + SU + BI
group increased marginally from baseline.
In the “China” group, the number of hypogly-
caemic episodes at three months were as follows:
1,237 episodes in the BIAsp-only group, 279
Table 4 (a) Daily BIAsp 30 dosage and number of injections at baseline, three months and six months—all exclude
China; (b) Daily BIAsp 30 dosage and number of injections at baseline and three months—China
BIAsp 30 only BIAsp 30 + SU BIAsp 30 + BI BIAsp 30 + SU + BI
Safety population 2,507 269 1,062 489
At treatment initiation
Mean total dose, N; U/kg bw  S.D. 2,465 264 1,044 485
0.47  0.19 0.29  0.15 0.42  0.18 0.30  0.15
Once daily, N (%) patients 277 (11.0) 126 (47.4) 165 (15.7) 218 (44.6)
Twice daily, N (%) patients 2,175 (86.9) 138 (51.9) 871 (82.5) 270 (55.3)
Thrice daily, N (%) patients 50 (2.0) 2 (0.8) 20 (1.9) 0 (0.0)
At three months
Mean total dose, N; U/kg bw  S.D. 2,283 254 934 464
0.53  0.21 0.34  0.17 0.48  0.18 0.34  0.16
Once daily, N (%) patients 240 (9.9) 112 (43.1) 113 (11.4) 182 (38.1)
Twice daily, N (%) patients 2,102 (86.9) 145 (55.8) 836 (84.8) 290 (60.6)
Thrice daily, N (%) patients 76 (3.1) 3 (1.2) 37 (3.8) 6 (1.3)
At six months
Mean total dose, N; U/kg bw  S.D. 2,129 235 910 401
0.55  0.21 0.38  0.19 0.53  0.20 0.36  0.18
Once daily, N (%) patients 220 (9.9) 91 (37.9) 97 (10.1) 161 (37.7)
Twice daily, N (%) patients 1,860 (84.0) 142 (59.2) 805 (83.9) 259 (60.8)
Thrice daily, N (%) patients 134 (6.1) 7 (2.9) 58 (6.0) 6 (1.4)
BIAsp 30 only BIAsp 30 + BI BIAsp 30 + GI BIAsp 30 + BI + TZD
Safety population 2,464 541 165 156
At treatment initiation
Mean total dose, N; U/kg bw  S.D. 2,462 539 164 156
0.44  0.15 0.42  0.14 0.43  0.16 0.49  0.10
Once daily, N (%) patients 0 0 0 0
Twice daily, N (%) patients 2,371 (96.2) 498 (92.1) 160 (97.0) 145 (92.9)
Thrice daily, N (%) patients 93 (3.8) 43 (7.9) 5 (3.0) 11 (7.1)
At three months
Mean total dose, N; U/kg bw  S.D. 2,462 541 164 156
0.48  0.15 0.46  0.14 0.48  0.14 0.58  0.15
Once daily, N (%) patients 0 0 0 0
Twice daily, N (%) patients 2,323 (94.3) 497 (91.9) 161 (97.6) 151 (96.8)
Thrice daily, N (%) patients 141 (5.7) 44 (8.1) 4 (2.4) 3 (1.9)
BI = biguanides; SU = sulphonylureas; GI = alpha-glucosidase inhibitors; TZD = thiazolidinediones.
Percentages may not total 100% because of rounding off.
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in the BIAsp 30 + GI group and 686 episodes in
the BIAsp 30 + BI + TZD group. When expressed
as the number of episodes/patient year, the
number of hypoglycaemic episodes/patient year at
the end of study vs. baseline were as follows: BIAsp
30-only group (2.01 vs. 6.91), BIAsp 30 + BI group
(2.06 vs. 6.38), and BIAsp 30 + GI group (1.67 vs.
8.82), BIAsp 30 + BI + TZD group (17.59 vs.
32.33). Generally the most frequent hypoglycae-
mic episodes were diurnal and minor in nature
(Figure 2). The rate of nocturnal episodes
increased slightly from baseline in the BIAsp
30 + BI + TZD group.
Table 5 (a) Change in glucose parameters from baseline—all exclude China; (b) Change in glucose parameters from
baseline—China
BIAsp 30 only BIAsp 30 + SU BIAsp 30 + BI BIAsp 30 + SU + BI
Safety population 2,507 269 1,062 489
Mean HbA1c,N ;% SD (95% CI)
At baseline 2,507 269 1,062 489
9.84  1.78 9.53  1.60 9.91  1.79 9.34  1.45
Change at three months of treatment 1,778 182 674 339
-1.58  1.61* -1.76  1.45* -1.91  1.77* -1.23  1.07*
(-1.66; -1.51) (-1.97; -1.55) (-2.04; -1.77) (-1.35; -1.12)
Change at six months of treatment 2,169 238 929 425
-2.12  1.76* -1.95  1.59* -2.24  1.77* -1.78  1.20*
(-2.19; -2.04) (-2.16; -1.75) (-2.35; -2.12) (-1.89; -1.66)
Mean FPG, N; mmol/L  SD (95% CI)
At baseline 2,428 261 1,018 488
13.00  4.06 11.75  3.37 12.42  3.67 10.73  3.00
Change at three months of treatment 2,262 250 935 478
-4.05  3.82* -3.22  2.92* -3.80  3.65* -2.78  2.48*
(-4.20; -3.89) (-3.58; -2.85) (-4.04; -3.57) (-3.01; -2.56)
Change at six months of treatment 2,088 233 896 427
-4.82  3.86* -3.98  3.19* -4.48  3.68* -3.57  2.78*
(-4.99; -4.66) (-4.39; -3.57) (-4.72; -4.24) (-3.83; -3.31)
Mean PPPG, N; mmol/L  SD (95% CI)
At baseline 2,392 255 1,008 483
17.56  4.82 16.75  4.34 16.93  4.46 15.71  4.02
Change at three months of treatment 2,231 230 919 472
-5.87  4.88* -5.32  4.12* -5.73  4.61* -4.42  3.55*
(-6.07; -5.67) (-5.85; -4.78) (-6.03; -5.43) (-4.74; -4.10)
Change at six months of treatment 2,042 229 888 421
-6.89  4.74* -6.25  4.45* -6.66  4.55* -5.89  3.98*
(-7.09; -6.68) (-6.83; -5.67) (-6.96; -6.36) (-6.27; -5.51)
BIAsp 30 only BIAsp 30 + BI BIAsp 30 + GI BIAsp 30 + BI + TZD
Safety population 2,464 541 165 156
Mean HbA1c,N ;% SD (95% CI)
At baseline 2,464 541 165 156
9.08  1.63 9.62  1.93 9.21  1.58 9.24  1.40
Change at three months of treatment 2,463 541 165 156
-2.16  1.52* -2.44  1.52* -2.33  1.41* -1.21  1.60*
(-2.22; -2.10) (-2.57; -2.31) (-2.55; -2.11) (-1.47; -0.96)
Mean FPG, N; mmol/L  SD (95% CI)
At baseline 2,462 541 165 145
10.47  2.61 11.39  2.91 11.53  2.63 10.75  2.42
Change at three months of treatment 2,454 541 165 145
-3.34  2.49* -4.01  2.50* -4.34  2.52* -3.50  2.29*
(-3.43; -3.24) (-4.22; -3.80) (-4.73; -3.95) (-3.87; -3.12)
Mean PPPG, N; mmol/L  SD (95% CI)
At baseline 2,463 541 165 155
15.44  4.03 16.60  4.21 17.43  4.04 15.28  3.81
Change at three months of treatment 2,459 541 165 155
-6.29  3.92* -7.10  3.96* -7.97  3.99* -5.97  3.39*
(-6.44; -6.13) (-7.44; -6.77) (-8.58; -7.35) (-6.51; -5.43)
*P < 0.001 (change from baseline; paired t-test).
BI = biguanides; CI = conﬁdence interval; FPG = fasting plasma glucose; PPPG = postprandial plasma glucose SU = sulphonylureas; GI = alpha-glucosidase
inhibitors; TZD = thiazolidinediones.
To convert mmol/L to mg/dL, multiply by 18.
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Epidemiological analysis of data from the UKPDS
study has shown that for every 1% point reduction
in HbA1c, the risks of microvascular complications
and myocardial infarction are reduced by 35% and
18%, respectively [3,19,20]. The mean HbA1c in
the insulin monotherapy and combination therapy
groups in this study were all reduced by approxi-
mately 2% points. This observation suggests that
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Figure 1 Hypoglycaemia at baseline and end of study stratiﬁed according to (a) time of day and (b) severity. End of study
(EOS) includes data from three and six months—all exclude China.
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Arch Drug Info 2009;2:23–33the reductions in HbA1c achieved by patients
receiving BIAsp could be associated with
decreased risks of diabetes-related complications
but this will need to be formally tested.
The improvements in HbA1c in this study were
consistent with the observations of a 16-week ran-
domised controlled trial of BIAsp 30 treatment in
patients with type 2 diabetes [16]. In that study, the
Figure 2 Hypoglycaemia at baseline and end of study stratﬁed according to (a) time of day and (b) severity—China.
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patients treated with insulin monotherapy and by
1.7% points in patients treated with insulin plus
metformin.
The glucose-lowering effectiveness of indi-
vidual therapies and combinations is dependent
not only on the intrinsic characteristics of the
intervention, but also on the baseline glycaemia,
duration of diabetes, previous therapy and other
factors [4]: many of these were not controlled in
the present study and thus comparisons in effec-
tiveness across the different intervention groups is
not meaningful. However, it is noteworthy that
diabetes control was improved in all the groups
studied.
Treatment Regimen
Although all the glucose parameters showed sig-
niﬁcant improvements at the end of the study, a
substantial proportion of patients did not achieve
the ADA recommended HbA1c target of less than
7%. This was probably because the study was not
conducted with a trial-to-target regimen and the
insulin dosage was not optimised. The eventual
dose requirements for patients with type 2 diabetes
around the world is expected to be 50 to 100 U per
day [21], which is much higher than the average
doses for our patients.
Limitations
This study was observational in nature and hence
had its inherent limitations. Patients were not ran-
domised to different therapies, nor was the dose of
insulin or other anti-diabetic agents controlled.
Thus, it is not possible to compare the responses
across the groups in a meaningful manner. The
method of data collection for hypoglycaemic epi-
sodes and ADRs was based on patient recollection,
which could have resulted in under-reporting.
Further, blood glucose measurements were not
recorded during hypoglycaemic episodes that
occurred prior to the start of the study. The study
was conducted over a short period and was inad-
equate for capturing long-term trends and obser-
vations. Therefore, the results should be taken
with some caution. However, the improvement in
measure of diabetes control in this large number of
patients enrolled in this study are concordant with
ﬁndings from randomised controlled trials.
Further, this study was carried out in a clinical
setting, which would be a closer reﬂection of the
“real-world” experience, as compared to highly
selected patients clinical trials.
Conclusions
The initiation of BIAsp 30 treatment in a clinical
setting, either in as a monotherapy or in combina-
tion with OADs, was observed to improve glycae-
mic control in patients with type 2 diabetes who
were poorly controlled on oral agents. This
improvement was accompanied with a low occur-
rence of major and nocturnal hypoglycaemic
episodes.
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